ARQT (Arcutis Biotherapeutics) Effective Interest Rate on Debt % : 12.80% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Arcutis Biotherapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Arcutis Biotherapeutics's annualized positive value of Interest Expense for the quarter that ended in Sep. 2024 was $26.6 Mil. Arcutis Biotherapeutics's average total debt for the quarter that ended in Sep. 2024 was $207.9 Mil. Therefore, Arcutis Biotherapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2024 was 12.80%.

Arcutis Biotherapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Arcutis Biotherapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcutis Biotherapeutics Effective Interest Rate on Debt % Chart

Arcutis Biotherapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

11.18

14.55

Arcutis Biotherapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															14.78	15.11	14.50	14.45	12.80

Competitive Comparison of Arcutis Biotherapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Arcutis Biotherapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcutis Biotherapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcutis Biotherapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Arcutis Biotherapeutics's Effective Interest Rate on Debt % falls into.

Arcutis Biotherapeutics Effective Interest Rate on Debt % Calculation

Arcutis Biotherapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2022 )	+	Total Debt (A: Dec. 2023 ))	/ count )
=	-1 * -29.712	/	( (202.543	+	205.916)	/ 2 )
=	-1 * -29.712	/	204.2295
=	14.55 %

where

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	201.886	+	0.657
=	202.543

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	205.181	+	0.735
=	205.916

Arcutis Biotherapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2024 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Jun. 2024 )	+	Total Debt (Q: Sep. 2024 ))	/ count )
=	-1 * -26.612	/	( (207.563	+	208.178)	/ 2 )
=	-1 * -26.612	/	207.8705
=	12.80 %

where

	Total Debt (Q: Jun. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	206.786	+	0.777
=	207.563

	Total Debt (Q: Sep. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	107.867	+	100.311
=	208.178

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Sep. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Arcutis Biotherapeutics (NAS:ARQT) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Arcutis Biotherapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Arcutis Biotherapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcutis Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcutis Biotherapeutics Inc (NAS:ARQT) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3027 Townsgate Road, Suite 300, Westlake Village, CA, USA, 91361

Website

https://www.arcutis.com

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Executives

Howard G. Welgus	director	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Larry Todd Edwards	officer: Chief Commercial Officer	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Todd Franklin Watanabe	director, officer: President and CEO	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Masaru Matsuda	officer: SVP and General Counsel	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Patrick Burnett	officer: See Remarks	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Terrie Curran	director	C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Matthew Richard Moore	officer: SVP and Chief Business Officer	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Patrick J Heron	director, 10 percent owner	550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301
Frazier Life Sciences Viii, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Scott L Burrows	officer: Chief Financial Officer	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Patricia A. Turney	officer: Senior VP, Manufacturing	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
David W Osborne	officer: Chief Technical Officer
Kenneth A. Lock	officer: Chief Commercial Officer	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Neha Krishnamohan	director	12707 HIGH BLUFF DRIVE, SAN DIEGO CA 92130
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022